Tumor Treating Fields (Optune) for Glioblastoma
Glioblastoma treatment now includes more than surgery, radiation, and chemotherapy. A wearable device called Optune adds a fourth option for many patients. This guide explains how Tumor Treating Fields work and what the evidence actually shows.
Request a Consultation
What Tumor Treating Fields Actually Are
Indeed, Tumor Treating Fields, often shortened to TTFields, use low-intensity electrical fields. These fields specifically target dividing cancer cells within the brain.
- Optune: the FDA-approved TTFields device made by Novocure
- Delivered through adhesive arrays placed on the shaved scalp
- Worn externally, not implanted or surgical in any way
- Approved specifically for newly diagnosed and recurrent glioblastoma
Novocure developed this technology after years of laboratory and clinical research. Our guide to glioblastoma explains where this treatment fits within the broader disease picture.
Unlike chemotherapy or radiation, TTFields work through physical, not chemical or radiation-based, mechanisms. This distinction matters because it creates a different side effect profile entirely. So, many patients tolerate Optune well even after intensive prior treatment.
How TTFields Work Against Cancer Cells
Certainly, cancer cells divide rapidly, far more often than most healthy adult brain cells. TTFields specifically disrupt this division process at the cellular level.
Specifically, the alternating electrical fields interfere with proteins that cancer cells need for division. As a result, affected cells struggle to divide normally and often die. Healthy, non-dividing brain cells generally experience much less disruption from these fields.
This selectivity forms the core scientific rationale behind the entire treatment approach.
| Concept | Simple Explanation |
|---|---|
| Alternating electric field | A field that rapidly changes direction at a specific frequency |
| Mitosis disruption | Interference with the physical process of cell division |
| Selective effect | Greater impact on rapidly dividing cancer cells than stable healthy cells |
The EF-14 Trial: What the Evidence Shows
Overall, the EF-14 trial remains the key study behind Optune's approval. Researchers enrolled 695 newly diagnosed glioblastoma patients across multiple countries.
| Outcome Measured | Temozolomide Alone | Temozolomide Plus Optune |
|---|---|---|
| Median overall survival | 16.0 months | 20.9 months |
| Five-year survival rate | 5% | 13% |
| Progression-free survival | Shorter | Extended by roughly 37% |
The FDA approved Optune for newly diagnosed glioblastoma in October 2015, based partly on this trial. Researchers later published the final EF-14 analysis in JAMA, confirming these survival benefits. This trial remains one of very few in over a decade to extend survival meaningfully for this diagnosis.
Overall, researchers designed the study carefully, adjusting for factors such as age and tumor genetics.
From Laboratory Research to Clinical Approval
Certainly, TTFields technology did not appear overnight. Instead, researchers spent years studying electric field effects on dividing cells before human trials began.
Early laboratory studies first showed that specific field frequencies could disrupt cancer cell division. Later, small clinical trials tested safety in real patients. Finally, the large EF-14 trial confirmed a genuine survival benefit, leading to FDA approval.
- Laboratory research on electric fields and cell division
- Early-phase human trials testing safety and feasibility
- The pivotal EF-14 Phase 3 trial in newly diagnosed patients
- FDA approval and integration into standard treatment guidelines
How Optune Compares with Other Treatment Additions
Indeed, glioblastoma treatment increasingly combines several approaches together. Comparing Optune against other additions helps clarify its specific, distinct role.
| Treatment Addition | How It Works | Typical Timing |
|---|---|---|
| Tumor Treating Fields (Optune) | Disrupts cancer cell division with electric fields | After radiation, alongside chemotherapy |
| Clinical trial therapies | Varies by specific study design | Depends on trial protocol and eligibility |
| Standard chemotherapy | Damages rapidly dividing cancer cell DNA | During and after radiation therapy |
These approaches are not mutually exclusive options. In fact, many patients use several together under careful medical supervision. Our clinical trials guide explains how trial participation might fit alongside Optune.
Who Is a Candidate for Optune Treatment
Certainly, Optune suits specific patient groups rather than every glioblastoma diagnosis. So, your neuro-oncology team evaluates several factors before recommending this device.
- Confirmed glioblastoma diagnosis, newly diagnosed or recurrent
- Completion of standard surgery and radiation therapy first
- Willingness to wear the device for the required daily duration
- No implanted electronic medical devices that could interact with the fields
Our treatment approaches page explains how Optune fits alongside surgery and other standard therapies. A second opinion can also help confirm whether this device suits your specific case. This confirmation matters especially for complex or borderline cases.
Daily Life While Wearing the Device
Certainly, Optune requires real commitment from patients and families. Generally, manufacturer guidance recommends wearing the device for at least eighteen hours daily for the strongest benefit.
- A technician or caregiver shaves the scalp regularly for proper array contact
- Adhesive arrays get placed on the scalp in a specific pattern
- A portable battery or power connection powers the device throughout the day
- Arrays get replaced every few days as adhesive quality declines
Many patients continue work, hobbies, and daily activities while wearing Optune. The device fits under hats or scarves for patients who prefer more privacy. So, most daily activities remain possible with some practical adjustment.
Planning ahead, particularly for travel or special occasions, helps this routine feel more manageable.
Traveling with Optune as an International Patient
Naturally, international patients often ask how Optune fits into travel plans. Fortunately, the device travels reasonably well with some advance planning.
- Portable battery packs allow use away from a power outlet
- Carry documentation explaining the device for airport security
- Confirm voltage and charger compatibility for your home country
- Arrange local technician support once you return home
Our surgery in Istanbul page describes the surgical phase that typically precedes Optune. Afterward, most patients continue Optune use closer to home, with periodic remote check-ins to review scans and daily usage data.
Support Resources for Patients Using Optune
Certainly, adjusting to daily device use takes real time and patience. Fortunately, several support resources exist specifically for this adjustment period.
- Novocure's own patient support program for device training and troubleshooting
- Online support communities connecting current Optune users
- Your local oncology nurse for skin care and practical questions
Connecting with other patients often eases early concerns about visibility or daily routine. So, ask your care team about available support resources early in the process, before frustration builds.
Combining Optune with Other Treatments
Importantly, Optune does not replace chemotherapy or radiation therapy. Instead, the EF-14 trial specifically studied Optune alongside temozolomide chemotherapy.
Generally, most newly diagnosed patients start Optune after finishing radiation therapy. Chemotherapy typically continues alongside the device during this phase. Our clinical trials guide covers newer research combining TTFields with other emerging therapies.
Potential Side Effects to Know About
Generally, skin irritation under the adhesive arrays represents the most common side effect. Generally, most cases stay mild and respond well to proper skin care guidance.
- Scalp irritation or redness beneath the arrays
- Occasional skin breakdown with prolonged use
- Mild discomfort during initial adjustment to the device
- Rare heat sensation during use, usually manageable
Regular array rotation and proper scalp hygiene reduce most skin problems significantly. Report any persistent or worsening skin issue to your care team promptly. Serious side effects beyond skin irritation remain uncommon in published trial data.
Occasionally, headache and mild discomfort occur during the first days of use. These symptoms usually settle as patients adjust to the device. Contact your care team promptly if any symptom feels severe or persistent.
Some patients also report mild anxiety related to visible arrays on the scalp. Support groups and honest conversation with family often ease this specific concern. So, address both the physical and emotional side of daily device use.
Common Misconceptions About Optune
Certainly, some patients misunderstand what this device can and cannot do. Clearing up these misconceptions helps set realistic, evidence-based expectations.
| Misconception | What the Evidence Actually Shows |
|---|---|
| Optune replaces surgery and chemotherapy | It works alongside these treatments, not instead of them |
| The device guarantees a cure | Trial data shows a survival benefit, not a guaranteed outcome |
| Any brain tumor qualifies for Optune | Approval covers specifically glioblastoma, under defined conditions |
| Wearing the device occasionally is enough | Benefit correlates with consistent daily usage time |
No treatment, including Optune, can promise a specific outcome for an individual patient. Therefore, discuss realistic expectations directly with your neuro-oncology team. A trustworthy team explains both the potential benefit and its real limits honestly.
Questions Worth Asking Your Care Team About Optune
Certainly, a good conversation about Optune covers more than basic eligibility. Preparing specific questions in advance helps you get complete, useful answers.
- When should I start Optune relative to my radiation schedule?
- How will we monitor my scalp for irritation over time?
- What happens if I cannot reach eighteen hours of daily use?
- How does Optune affect my ability to travel or work?
- What follow-up imaging schedule accompanies this treatment?
Write down the answers, or ask a family member to take notes. Afterward, review this information together before making a final decision.
What Experience Adds to Optune Treatment Planning
Indeed, Prof. Dr. Serdar Baki Albayrak has practiced neurosurgery for more than 27 years, treating patients from 64 countries. This experience shapes how our team sequences surgery, radiation, and additions like Optune together.
Coordinating multiple treatment phases requires careful planning, not just individual expertise. Therefore, our team works closely with neuro-oncology colleagues to plan this sequence properly. Our scientific publications and case studies page reflects this coordinated, evidence-based approach.
Cost and Access Considerations
Generally, Optune involves an ongoing device rental cost, separate from surgery and hospital fees. This cost structure differs from a one-time surgical package.
Our treatment cost guide explains how device costs fit alongside surgery and systemic therapy in an overall plan. Insurance coverage for Optune varies considerably by country and specific policy. So, confirm this coverage well before starting treatment to avoid unexpected costs.
- Ask your insurer directly about TTFields device coverage
- Request documentation from your care team to support any claim
- Clarify rental duration and any ongoing fees before starting treatment
Getting Started with Optune
Certainly, starting Optune involves coordination between your surgical, oncology, and device provider teams. Our team helps confirm candidacy and connect this step to your overall treatment plan, so nothing falls through the cracks between specialists.
- Complete surgery and radiation therapy as planned
- Discuss Optune candidacy with your neuro-oncology team
- Arrange device fitting and initial scalp shaving with a trained technician
- Begin daily use, aiming for the recommended eighteen-plus hours
Contact our team to discuss whether Optune fits into your treatment plan. We also address questions about sequencing this device alongside surgery and chemotherapy.
Next Steps Toward a Complete Treatment Plan
Overall, Optune works best as one piece of a coordinated overall plan. So, discuss it alongside surgery, radiation, and systemic therapy, not in isolation.
- Complete your surgical consultation and imaging review
- Discuss radiation and chemotherapy planning with your oncology team
- Ask specifically whether and when Optune fits your case
- Request a written plan covering every treatment phase together
Our team welcomes this broader planning conversation from the very start. Reach out today to begin building your complete treatment plan, with every phase considered together from day one.
How Our Practice Approaches Optune Recommendations
Certainly, not every patient benefits equally from adding Optune to their plan. So, our team reviews each case individually before making a specific recommendation.
- Review of tumor genetics and overall prognosis
- Discussion of realistic daily commitment and lifestyle factors
- Coordination with radiation and chemotherapy timing
- Honest conversation about expected benefit versus burden
This individualized approach reflects broader evidence-based practice, not a one-size-fits-all protocol. Our treatment approaches page describes this broader philosophy in more detail, covering surgery, radiation, and systemic therapy together.
Realistic Expectations for Any Individual Patient
Certainly, trial averages describe groups, not individual guarantees. So, one patient's actual experience may differ meaningfully from the published averages.
Factors such as tumor genetics, overall health, and treatment adherence all shape individual outcomes. Therefore, discuss your specific prognosis honestly with your neuro-oncology team, rather than relying only on population statistics. Our case studies and publications page offers additional context beyond the headline trial numbers, grounded in real clinical experience.
Frequently Asked Questions
Does Optune replace chemotherapy for glioblastoma?
No, the EF-14 trial studied Optune specifically alongside temozolomide chemotherapy. The device works as an addition to standard treatment, not a replacement. Most patients continue chemotherapy while using the device.
How many hours per day do patients need to wear Optune?
Manufacturer guidance recommends at least eighteen hours of daily use. Studies suggest higher usage correlates with stronger survival benefit. Your care team helps you build a realistic daily wearing routine.
What survival benefit did the EF-14 trial actually show?
Median overall survival reached 20.9 months with Optune plus temozolomide, compared with 16.0 months for temozolomide alone. Five-year survival also rose from 5% to 13%. These results reflect group averages, not individual guarantees.
Does Optune cause serious side effects?
Scalp irritation under the arrays represents the most common side effect. Most cases stay mild and improve with proper skin care. Serious side effects beyond skin issues remain uncommon in published data.
Does Optune's approval also cover recurrent glioblastoma?
Yes, TTFields received approval for recurrent glioblastoma before the newly diagnosed indication. Eligibility still depends on individual factors and prior treatment history. Discuss your specific situation with your neuro-oncology team.
How does treatment cost planning work for a device like Optune?
Device costs typically involve an ongoing rental structure, separate from surgical fees. Insurance coverage varies significantly by country and policy. Our cost guide explains how to plan for this alongside other treatment expenses.
Can I travel internationally while using Optune?
Yes, many patients travel while using the device successfully. A portable battery pack allows use away from a fixed power source. Plan documentation and charger compatibility in advance for smoother travel.
Does hair need to stay shaved for the entire treatment period?
Yes, regular shaving keeps the arrays in proper contact with the scalp. A caregiver or technician typically handles this every few days. Consistent contact directly affects how well the device delivers its intended fields.
Indeed, poor contact can reduce the effective dose reaching the tumor site significantly.
Which company makes Optune, and does the FDA approve it?
Indeed, Novocure manufactures Optune, and the FDA approved it for glioblastoma treatment. Approval covers both newly diagnosed and recurrent disease, under specific conditions. Ask your care team to confirm how this approval applies to your specific diagnosis and stage.
What happens if I stop using Optune early?
Stopping early remains entirely your choice, without penalty of any kind. However, published data indeed suggests consistent use correlates with stronger benefit. Discuss any concerns about continuing use openly with your care team.
Disclaimer: This page is provided for informational purposes only and does not constitute medical advice. Statistics represent published group averages and cannot predict any individual outcome. Always consult Prof. Dr. Serdar Baki Albayrak or another qualified physician directly regarding any medical condition, symptoms, or treatment decisions.
Discuss Your Case With Our Team
Send your MRI report and pathology details for a structured, honest opinion from an experienced brain tumor surgeon in Istanbul.
Request a ConsultationRequest an Appointment
Do you have questions about your diagnosis or treatment options? Send your details below, and our team will contact you to schedule a consultation.